The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis

Pfizer256 enrolled

Overview

Anidulafungin is a medicine being developed for treatment of patients with certain kinds of fungal infections. These infections due to yeast (a type of fungus) in the mouth/esophagus, in the blood or in other areas within the body.

Anidulafungin is an investigational drug being developed as an intravenous treatment for esophageal candidiasis, candidemia and other invasive fungal infections. Anidulafungin is an antifungal agent of the echinocandin class, which targets the fungal cell wall of yeast and other filamentous fungi.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

256

Conditions

Candidiasis

Interventions

AnidulafunginDRUG

FluconazoleDRUG

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

* Diagnosis of candidemia and/or other forms of invasive candidiasis. * Should not have received greater than 48 hours of systemic antifungal therapy. * Life expectancy should be greater than 72 hours. * Should not have received greater than one week of prophylactic azole therapy 30 days prior to enrollment

Locations (1)

Versicor, Inc.

King of Prussia, Pennsylvania, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.